Form 8-K - Current report:
SEC Accession No. 0001193125-25-160293
Filing Date
2025-07-17
Accepted
2025-07-17 08:40:20
Documents
14
Period of Report
2025-07-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d948144d8k.htm   iXBRL 8-K 25617
2 EX-99.1 d948144dex991.htm EX-99.1 8413
6 GRAPHIC g948144dsp001.jpg GRAPHIC 6660
  Complete submission text file 0001193125-25-160293.txt   157750

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20250717.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20250717_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20250717_pre.xml EX-101.PRE 10817
17 EXTRACTED XBRL INSTANCE DOCUMENT d948144d8k_htm.xml XML 3727
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 251128968
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)